Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab for Upfront Therapy in High Risk AL Amyloidosis
NCT04754945Phase 1Active, not recruiting
- Sponsor
- Emory University
- Start
- Apr 2021
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of isatuximab in amyloid light chain amyloidosis, sponsored by Emory University. Primary endpoint: Event-free proportion at 3 months. Started Apr 2021; status: active, not recruiting.
02
Drugs
isatuximab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT04754945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04754945.